Female patients must have a negative pregnancy test (blood or urine) within  days prior to registration
WOCBP must have a negative pregnancy test (serum or urine).
Negative serum or urine pregnancy test within  days prior to starting treatment
Negative urine pregnancy test done =<  days prior to registration, for women of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients must have a negative urine pregnancy test within  days prior to registration; if urine test is positive, it should be followed by serum pregnancy test
FCBP must have a negative serum or urine pregnancy test and agree to birth control.
If female, the subject must have a negative serum or urine pregnancy test at Screening unless meeting non-productive potential criteria.
Either of non-reproductive potential (i.e., post-menopausal by history of age >=  years old and no menses for >=  year without an alternative medical cause; OR history of hysterectomy, history of bilateral tubal ligation, or history of bilateral oophorectomy) OR must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; subjects with a negative pregnancy test at screening beyond  hours prior to treatment, but who otherwise meet all other criteria, may be registered to trial but must have a repeat negative serum pregnancy test within  hours of treatment and such testing may be done on day of first treatment prior to administration
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within  hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  days of study registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female of childbearing potential: negative urine or serum pregnancy test, performed within  days prior to day  of protocol therapy\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy test done =<  hours prior to first treatment, for women of childbearing potential only\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential should have a negative pregnancy test within  days prior to on-study date; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be required
Females of childbearing potential must have a negative pregnancy test within  days prior to on study status; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be required
Negative pregnancy test done =<  days prior to registration, for persons of childbearing potential only (POCBP)\r\n* NOTE: Serum or urine pregnancy test allowed; if urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential must have a negative pregnancy test (either urine or serum pregnancy test) within  hours prior to the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
Female subject of childbearing potential should have a negative urine or serum pregnancy; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
To be performed within  business days prior to day : Female of childbearing potential: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Within  days prior to planned start of treatment: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Has negative serum or urine pregnancy test for subjects of childbearing potential within  days before first dose.
A negative urine dipstick pregnancy test
Female subject of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  days of initiating SBRT; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy test (female of childbearing potential only)\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
FOCBP must have a negative urine or serum pregnancy test within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Patients of childbearing potential must have a negative urine or serum pregnancy test =<  days prior to registration\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  days prior to study registration up to the first fraction of radiation; \r\n* Note: if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential (WOCBP) (free from menses for >  years, post hysterectomy/oophorectomy, or surgically sterilized) must have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative a serum pregnancy test will be required to be shown as negative for the patient to be eligible
Has negative serum or urine pregnancy test for subjects of childbearing potential
Negative urine pregnancy test and/or serum pregnancy test within  days of initiation of therapy
Negative serum or urine pregnancy test
Female patient of childbearing potential has a negative urine or serum pregnancy test within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
For Phase I and II: Negative urine or serum pregnancy test.
Negative pregnancy test (serum or urine) in premenopausal women
Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past  months and without sterilization surgery
Negative pregnancy test done =<  days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  days of enrollment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine pregnancy test at baseline.
Negative blood or urine pregnancy test at screening
For childbearing female patients, negative serum or urine pregnancy test at screening
A negative serum or urine pregnancy test during Screening,
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Negative urine/serum pregnancy test (females only) at the time of screening and within  hours of study treatment, if applicable
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
Within  days prior to day  of protocol therapy unless otherwise stated: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female participants of childbearing potential must have a negative serum pregnancy test at screening and negative (serum or urine) pregnancy test within  hours before the first study-drug dose; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the participant to be eligible
To be performed within  days prior to day  of protocol therapy: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
A WOCBP who has a positive urine pregnancy test within  hours prior to study treatment start; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Woman of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative pregnancy test done =<  days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* NOTE: Merck requires an additional pregnancy test if eligibility pregnancy test is >  hours prior to first dose
Female subject of childbearing potential should have a negative urine or serum pregnancy per institutional guidelines for high-dose melphalan and autologous transplant; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Females only:\r\n* Urine or serum pregnancy test negative assessed within seven () days prior to the start of therapy
And have a negative urine pregnancy test at Screening
Have a negative urine or serum pregnancy test at screening
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test)
Negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least  mIU/mL) within  hours prior to starting IP in the extension phase. (Note: subjects must have negative serum or urine pregnancy test prior to dosing on Day  of each treatment cycle in the extension phase.)
Negative urine/serum pregnancy test, if applicable
Negative serum or urine pregnancy test within  days prior to start of study treatment.
Negative urine pregnancy test
Female of childbearing potential only: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (within  days prior to day  of protocol therapy)
And have a negative urine or serum pregnancy test at screening
Female subjects of childbearing potential must have a negative serum pregnancy test within  days prior to study entry (positive urine tests are to be confirmed by serum test)
Negative urine or serum pregnancy test done =<  days prior to registration for females who are post-menarchal
Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within  hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
must have a negative urine pregnancy test at Screening, and
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
Positive serum or urine pregnancy test
Patients who are pregnant; pregnancy will be confirmed by negative urine test
Female patients must have a negative urine or serum pregnancy test at screening (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are >  year postmenopausal)
Urine pregnancy test for women of childbearing potential (defined as not post-menopausal for  consecutive months or no previous surgical sterilizations); a negative urine pregnancy test is required within  hours of initiating study drug
Negative serum or urine pregnancy test at the time of first dose for WOCBP.
Negative urine pregnancy test (negative serum confirmatory pregnancy test if urine test is positive)
Female subjects of childbearing potential must have either a negative urine or a negative serum pregnancy test within seven () days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential, must have either a negative urine or a negative serum pregnancy test within seven () days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Patients who are pregnant; the absence of pregnancy will be confirmed by negative urine test
Negative pregnancy test (urine and blood tests)
A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  days prior to C-AMT PET scan; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
If of childbearing potential, negative pre-treatment urine or serum pregnancy test
And have a negative urine or serum pregnancy test at screening
Female patients must have a negative urine pregnancy test
A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential
